tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Veru (VERU), Otonomy (OTIC) and Karuna Therapeutics (KRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veru (VERUResearch Report), Otonomy (OTICResearch Report) and Karuna Therapeutics (KRTXResearch Report) with bullish sentiments.

Veru (VERU)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Veru today and set a price target of $24.00. The company’s shares closed last Monday at $13.31.

According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.4% and a 32.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Veru with a $30.33 average price target, a 108.2% upside from current levels. In a report issued on July 11, Oppenheimer also reiterated a Buy rating on the stock with a $36.00 price target.

See today’s best-performing stocks on TipRanks >>

Otonomy (OTIC)

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Otonomy, with a price target of $5.50. The company’s shares closed last Monday at $1.95.

According to TipRanks.com, Livnat is a 1-star analyst with an average return of -2.8% and a 39.9% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Satsuma Pharmaceuticals.

Currently, the analyst consensus on Otonomy is a Moderate Buy with an average price target of $5.50.

Karuna Therapeutics (KRTX)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Karuna Therapeutics, with a price target of $160.00. The company’s shares closed last Monday at $127.92.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -37.8% and a 18.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Timber Pharmaceuticals.

Karuna Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $177.13, representing a 37.7% upside. In a report issued on July 14, SVB Securities also initiated coverage with a Buy rating on the stock with a $170.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VERU:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More